Annexon Inc. (ANNX)
NASDAQ: ANNX
· Real-Time Price · USD
2.43
-0.06 (-2.41%)
At close: Jun 16, 2025, 3:59 PM
2.46
1.23%
Pre-market: Jun 17, 2025, 04:00 AM EDT
-2.41% (1D)
| Bid | 2.26 |
| Market Cap | 266.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.38M |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | -2.08 |
| Forward PE | -1.72 |
| Analyst | Buy |
| Ask | 2.88 |
| Volume | 507,412 |
| Avg. Volume (20D) | 1,815,712 |
| Open | 2.50 |
| Previous Close | 2.49 |
| Day's Range | 2.40 - 2.52 |
| 52-Week Range | 1.28 - 7.85 |
| Beta | 1.26 |
About ANNX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANNX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-5.52%
Annexon shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
+13.96%
Annexon shares are trading higher after the company announced topline results from a study supporting Anx005 as a potential treatment for Guillain-barré syndrome.
2 months ago · seekingalpha.com
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On DeckAnnexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 mi...